Clinical Trial Update: Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial [Phase 3]

View source ↗

Summary

Phase 3 trial update on extended prophylaxis with rivaroxaban in medically ill hospitalized COVID-19 patients to prevent thrombosis (MICHELLE Trial).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Science Valley Research Institute | Conditions: Covid19, Venous Thromboembolism | Phase 3 | Status: COMPLETED